Fails 1 of 8 criteria. S5, analytical documentation: No certificate of analysis or lot document is published on the product pages, the trust and compliance page or the policies. The product pages say only that the pharmacy and platform partners hold certifications such as PCAB.
At a glance
Mint MedTelehealth service
7/8criteria passed
Price
Semaglutide $106 a month, or from $86 prepaid for 12 months; tirzepatide $145, or from $125
Sells
compounded semaglutide, compounded tirzepatide, sermorelin, and 3 more
Telehealth service. Passes 7 of 8 criteria. Recorded against Standard v1.1.
An online telehealth platform in 35 states selling compounded semaglutide and tirzepatide at one price for every dose, with prepaid plans, plus sermorelin, NAD+, MIC+B12 and bremelanotide. Care starts with an online eligibility form before checkout, it names two filling pharmacies with street addresses, and an FDA warning letter names its operating company.
Mint Med's compounded semaglutide GLP-106 MO product page; Mint Med's compounded tirzepatide GLP GIP MO product page; Mint Med's weight management category page
The evidence behind each disposition in the table above, where it appears, and its date.
S1PASSA licensed provider reviews each intake and decides whether treatment is appropriate, holding a video or audio visit where the state requires one, and the about page names the founding physician, Dr. Roderick Huff, MD.Source: Mint Med's website; Mint Med's about page.
S2PASSThe how-it-works page lists an eligibility form of medical questions as the first step, which ends at once on a disqualifying answer, and only then the plan choice and checkout, followed by intake forms and a provider's review. The answers say payment is collected before the clinical review and refunded at once if the patient is not eligible, and the product pages show a check-if-you-qualify button.Source: Mint Med's how it works page; Mint Med's website; Mint Med's compounded semaglutide GLP-106 MO product page.
S3PASSThe answers and the privacy policy name the pharmacy fulfillment partners with street addresses: RxCompoundStore Pharmacy at 1 N. Federal Hwy, Fort Lauderdale, Florida, and Southend Pharmacy at 9301 Southwest Freeway, Suite 100, Houston, Texas.Source: Mint Med's contact page; Mint Med's privacy policy.
S4PASSThe product pages and the answers state that compounded semaglutide and tirzepatide are not FDA-approved, have not been reviewed by the FDA for safety, effectiveness or quality, and are not generic equivalents of any approved GLP-1 medication.Source: Mint Med's compounded semaglutide GLP-106 MO product page; Mint Med's website.
S5FAILNo certificate of analysis or lot document is published on the product pages, the trust and compliance page or the policies. The product pages say only that the pharmacy and platform partners hold certifications such as PCAB.Source: Mint Med's compounded semaglutide GLP-106 MO product page; Mint Med's trust and compliance page.
S6PASSGlow Medispa, LLC, doing business as Mint Med, at 8833 Chapel Square Dr., Cincinnati, OH 45249, printed as the mailing address on the contact information page and as the corporate office in the privacy policy. The terms name the operator as Mint Med, LLC and name Delaware law.Source: Mint Med's contact information page; Mint Med's privacy policy; Mint Med's terms of service page.
S7PASSCompounded semaglutide at $106 a month month to month, or $101, $96, $91 or $86 a month prepaid for 2, 3, 6 or 12 months, billed $202, $288, $546 or $1,032, at every dose. Compounded tirzepatide at $145 a month month to month, or $140, $135, $130 or $125 a month prepaid, billed $280, $405, $780 or $1,500. Every product page also shows a tirzepatide plan at $110 a month, billed $220 every 2 months, which the weight management page gives as the starting price. NAD+ costs $189 a month, sermorelin $120 every 5 weeks and MIC+B12 $150 for a 60-day supply.Source: Mint Med's compounded semaglutide GLP-106 MO product page; Mint Med's compounded tirzepatide GLP GIP MO product page; Mint Med's weight management category page.
S8PASSFDA warning letter 730390, June 2026, names Glow Medispa, LLC doing business as Mint Med at the Cincinnati, Ohio address the site prints, and it reviewed the seller's own website. It alleges that pictured labels identify Mint Med as the compounder of its semaglutide and tirzepatide products when it is not. No FDA action has halted the business, and the seller still trades.Source: FDA's website; FDA warning letter 730390.
Products shown on the seller's own pages at the recorded date: compounded semaglutide, compounded tirzepatide, sermorelin, NAD+, MIC+B12 injections, bremelanotide.
A warning letter alleges violations and requests a response. It does not halt a business, and it does not remove a seller from this ledger. Every letter recorded here.
Dispositions recorded against Standard v1.1. Method and null semantics: how checks are performed. This record is not a review and contains no medical advice.